FABIOR

Peak

tazarotene

NDATOPICALAEROSOL, FOAM
Approved
May 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
10

Mechanism of Action

form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Tazarotenic acid binds to all 3 members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ and RARγ and may modify gene expression. The clinical…

Pharmacologic Class:

Retinoid

Clinical Trials (5)

NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020
NCT04071756Phase 2Terminated

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
NCT01119651Phase 1Completed

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

Started Jun 2010
59 enrolled
Acne Vulgaris
NCT01115322Phase 1Completed

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

Started Apr 2010
38 enrolled
Acne Vulgaris
NCT01114841Phase 1Completed

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers

Started Mar 2010
254 enrolled
Acne Vulgaris

Loss of Exclusivity

LOE Date
Feb 24, 2030
48 months away
Patent Expiry
Feb 24, 2030

Patent Records (3)

Patent #ExpiryTypeUse Code
10568859
Feb 24, 2030
Product
U-2760
10688071
Feb 24, 2030
Product
U-2760
8808716
Feb 24, 2030
Product